NYMC Faculty Publications

Use of Ranolazine in Patients With Stable Angina Pectoris

Author Type(s)

Faculty

DOI

10.1159/000358871

Journal Title

Cardiology

First Page

251

Last Page

258

Document Type

Article

Publication Date

1-1-2014

Department

Medicine

Keywords

Acetanilides, Adrenergic beta-Antagonists, Angina, Stable, Calcium Channel Blockers, Delayed-Action Preparations, Drug Administration Schedule, Drug Therapy, Combination, Enzyme Inhibitors, Glycated Hemoglobin, Humans, Nitrates, Piperazines, Randomized Controlled Trials as Topic, Ranolazine, Treatment Outcome

Disciplines

Medicine and Health Sciences

Abstract

The current American Heart Association/American College of Cardiology guidelines for patients with stable angina pectoris recommend β-blockers as the initial drug therapy for prevention of angina pectoris (class I B indication). Long-acting nitrates or calcium channel blockers should be prescribed for prevention of angina when β-blockers are contraindicated or not tolerated secondary to side effects (class I B indication). Long-acting nitrates or calcium channel blockers in combination with β-blockers should be prescribed for angina prevention when initial treatment with β-blockers is unsuccessful (class I B indication). Only sublingual nitroglycerin or nitroglycerin spray should be used for immediate relief of angina pectoris (class I B indication). Ranolazine with β-blockers can be used for prevention of angina when initial treatment with β-blockers is not successful (class IIa A indication). If angina persists despite treatment with β-blockers, long-acting nitrates and calcium channel blockers, we recommend the addition of ranolazine for prevention of stable angina pectoris. This editorial discusses the contemporary role of ranolazine in the management of patients with stable angina pectoris.

Link to Full Text

Share

COinS